Aroa Biosurgery Limited (AROAF)

Market Cap	135.62M +23.3%
Revenue (ttm)	52.42M +18.4%
Net Income	-1.06M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	52.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Average Volume	28,064
Open	0.5220
Previous Close	0.5197
Day's Range	0.5220 - 0.5220
52-Week Range	0.2439 - 0.5220
Beta	0.80
RSI	n/a
Earnings Date	May 31, 2026

About Aroa Biosurgery

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that de...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2007
• Country: New Zealand
• Stock Exchange: OTCMKTS
• Ticker Symbol: AROAF

Financial Performance

In fiscal year 2025, Aroa Biosurgery's revenue was 84.70 million, an increase of 22.63% compared to the previous year's 69.07 million. Losses were -3.81 million, -64.12% less than in 2024.

Financial numbers in NZD